Skip to content

BDX

Becton, Dickinson and Company

NYSE · USHealthcareMedical - Instruments & Supplies
$154.48-2.33%

Price as of Jul 20, 2026

BDX growth

Becton, Dickinson and Company growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
+2.4%
EBITDA
+0.7%
EBIT
+2.0%
EPS
-24.8%
Free cash flow
+21.3%
Operating cash flow
+18.2%

Forward estimates

Revenue
-8.5%
EBITDA
-3.5%
EPS
+240.4%

Three-year CAGR

Revenue
+5.0%
EBITDA
+4.0%
EBIT
+4.1%
Net income
-1.9%
EPS
-0.5%
Free cash flow
+17.2%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.